MedTrace Logo

Evaluation of the Efficacy of Intramuscular Islet Autograft After Extensive Pancreatectomy

NCT02872571 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2026-04-22

No results posted yet for this study

Summary

The liver may not be an optimal site for islet transplantation due to obstacles by an instant blood-mediated inflammatory response, and low revascularization of transplanted islets. Therefore, intramuscular islet transplantation offers an attractive alternative, based on its simplicity, enabling easier access for noninvasive graft imaging and cell explantation.

Conditions

  • Disorder of Endocrine Pancreas

Interventions

DRUG

Intramuscular Islet Autograft

Intramuscular Islet Autograft After Extensive Pancreatectomy

Sponsors & Collaborators

  • University Hospital, Lille

    lead OTHER

Principal Investigators

  • François Pattou, MD, PhD · University Hospital, Lille

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2026-04-30
Completion
2026-04-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02872571 on ClinicalTrials.gov